Drug protein binding can impact both the pharmacokinetics (absorption, distribution and clearance) and pharmacodynamics (receptor/enzyme interaction) of a drug. Among all the proteins that drugs can potentially bind to, binding to plasma proteins and more specifically to human serum albumin, is of significance. Thus, estimation of plasma protein binding is an important part of characterization of a new chemical entity during its development into a drug. Methods to determine plasma protein binding can be broadly divided into methods that either involve or obviate the need for prior separation of protein‐bound and unbound drug. Methods requiring no separation of bound and unbound drug include surface plasmon resonance, capillary electrophoresis, NMR, fluorescence spectroscopy, etc., while equilibrium dialysis, ultracentrifugation, ultrafiltration, microdialysis, involve pre‐separation of bound and free drug for the determination of free fraction of the drug. Some of the methods are amenable to automation and high throughput requirements of drug discovery, but equilibrium dialysis is still considered the ‘gold standard’ for estimation of drug protein binding.